OOIR: Observatory of International Research

Papers

(The H4-Index of AIDS is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Gut microbiota and plasma metabolites associated with bone mineral density in women with or at risk of HIV infection	93
Keeping up with Streptococcus pneumoniae in children living with HIV: Erratum	83
Real world use of dolutegravir two drug regimens	77
The need to avert emergent resistance to dolutegravir in children and adolescents with HIV	72
A new frontier in HIV care: the predictive power of renal biomarkers on heart health	68
Associations between social determinants of health and comorbidity and multimorbidity in people of black ethnicities with HIV	41
Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance!	40
Key milestones and participant engagement strategies in research with HIV-affected adolescents and young adults from low-to-middle income countries	40
Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure – two nationwide, population-based cohort studies	39
Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery	39
Long-term persistence of transcriptionally-active “defective” HIV-1 proviruses: Implications for persistent immune activation during antiretroviral therapy	39
Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV	39
Explaining racial and ethnic disparities in antiretroviral therapy adherence and viral suppression among U.S. men who have sex with men	37
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy	36
Virtual case management: a differentiated approach to HIV prevention, treatment, and care	30
Quantifying missed opportunities for tuberculosis among people with HIV in the US President's Emergency Plan for AIDS Relief	29
Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabine	29
Survival following screening and preemptive antifungal therapy for subclinical cryptococcal disease in advanced HIV infection	28
Social context and tracing household wealth over time in rural Uganda 1994–2018	28
HIV-1 gp120 amplifies astrocyte elevated gene-1 activity to compromise the integrity of the outer blood–retinal barrier	27
Strategies for managing weight gain associated with antiretroviral therapy: switch or add?	27
Life expectancy of people with HIV on antiretroviral therapy in Spain	26
Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV	26
Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France	26
Elevated stress-responsive biomarkers are associated with HIV acquisition in young women in rural South Africa	25